nerve conduction study
Othernerve conduction study
NCT Number: NCT03499158
Terminal latency index, residual latency and median ulnar F latency difference in carpal tunnel syndrome are specific parameters for the diagnosis
Looking for future studies?
Notify Me18 year–90 year
All sexes
Observational
Carpal tunnel syndrome is the most common compression neuropathy. This study was performed to determine the value of terminal latency index, residual latency and median ulnar F latency difference to investigate their sensitivity and specificity in the diagnosis of this syndrome.
We retrospectively determined the 160 patients. We evaluated the nerve conduction studies of patient and healthy arms. We recorded all nerve conduction study values.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
nerve conduction study
Time frame: one month
ASLIHAN UZUNKULAOGLU
Other
Role of Terminal Latency Index, Residual Latency and Median Ulnar F Latency Difference in Carpal Tunnel Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07724717
Carpal Tunnel Syndrome, Cumulative Trauma Disorders
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT07105540
Carpal Tunnel Syndrome, Cumulative Trauma Disorders
Ankara, Yenimahalle, Turkey (Türkiye)
View Trial DetailsNCT05859412
Carpal Tunnel Syndrome, Cumulative Trauma Disorders
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT06414746
Amyloidosis, Amyloidosis, Hereditary, Transthyretin-Related
Arkhangelsk, Russia
View Trial Details